BR0112212A - Uma combinação de inibidores de fbpase e agentes antidiabéticos úteis para o tratamento de diabetes - Google Patents

Uma combinação de inibidores de fbpase e agentes antidiabéticos úteis para o tratamento de diabetes

Info

Publication number
BR0112212A
BR0112212A BR0112212-6A BR0112212A BR0112212A BR 0112212 A BR0112212 A BR 0112212A BR 0112212 A BR0112212 A BR 0112212A BR 0112212 A BR0112212 A BR 0112212A
Authority
BR
Brazil
Prior art keywords
combination
antidiabetic agents
agents useful
treating diabetes
fbpase inhibitors
Prior art date
Application number
BR0112212-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul D Van Poelje
Mark D Erion
Toshihiko Fujiwara
Original Assignee
Metabasis Therapeutics Inc
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc, Sankyo Co filed Critical Metabasis Therapeutics Inc
Publication of BR0112212A publication Critical patent/BR0112212A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0112212-6A 2000-07-06 2001-07-05 Uma combinação de inibidores de fbpase e agentes antidiabéticos úteis para o tratamento de diabetes BR0112212A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
PCT/US2001/021557 WO2002003978A2 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Publications (1)

Publication Number Publication Date
BR0112212A true BR0112212A (pt) 2003-12-30

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112212-6A BR0112212A (pt) 2000-07-06 2001-07-05 Uma combinação de inibidores de fbpase e agentes antidiabéticos úteis para o tratamento de diabetes

Country Status (18)

Country Link
EP (1) EP1372660A2 (no)
JP (1) JP2004508297A (no)
KR (1) KR100854851B1 (no)
CN (2) CN100396283C (no)
AU (2) AU2001273271B2 (no)
BR (1) BR0112212A (no)
CA (1) CA2412142A1 (no)
CZ (1) CZ20035A3 (no)
HU (1) HUP0301830A3 (no)
IL (2) IL153513A0 (no)
MX (1) MXPA02012713A (no)
NO (1) NO20030034L (no)
NZ (1) NZ523227A (no)
PL (1) PL365779A1 (no)
RU (1) RU2328308C2 (no)
SK (1) SK62003A3 (no)
WO (1) WO2002003978A2 (no)
ZA (1) ZA200300044B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE69910045T2 (de) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
CZ20023018A3 (cs) 2000-03-08 2003-01-15 Metabasis Therapeutics, Inc. Nové inhibitory fruktóza-1,6-bisfosfatázy obsahující arylovou skupinu
MXPA04002751A (es) 2001-09-24 2005-09-08 Univ Oregon Health & Science Modificacion del comportamiento de alimentacion.
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
AU2004309279B2 (en) 2003-12-26 2010-07-15 Kyowa Kirin Co., Ltd. Thiazole derivative
WO2006023515A2 (en) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
KR20070086007A (ko) * 2004-12-13 2007-08-27 다이이찌 산쿄 가부시키가이샤 당뇨병의 치료를 위한 의약 조성물
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
UY35065A (es) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd Fármaco combinado que comprende gemigliptina y metformina y método para su preparación
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504728A (ja) * 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ，インコーポレイテッド Ａｉｃａリボシドの放出および血液グルコースの低減のための化合物および方法
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
EP0970095B1 (en) * 1997-03-07 2003-10-29 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6107274A (en) * 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
DE69910045T2 (de) * 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
BR9917005A (pt) * 1998-12-24 2002-04-02 Metabasis Therapeutics Inc Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
DE60124861T2 (de) * 2000-01-21 2007-05-10 Novartis Ag Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
CZ20035A3 (cs) 2003-05-14
AU2001273271B2 (en) 2006-01-05
CN101301294A (zh) 2008-11-12
JP2004508297A (ja) 2004-03-18
WO2002003978A2 (en) 2002-01-17
RU2328308C2 (ru) 2008-07-10
IL153513A0 (en) 2003-07-06
NO20030034L (no) 2003-03-05
NO20030034D0 (no) 2003-01-03
PL365779A1 (en) 2005-01-10
SK62003A3 (en) 2003-09-11
MXPA02012713A (es) 2004-09-10
IL153513A (en) 2014-07-31
HUP0301830A3 (en) 2007-10-29
HUP0301830A2 (hu) 2003-11-28
KR100854851B1 (ko) 2008-08-27
CN1599612A (zh) 2005-03-23
CA2412142A1 (en) 2002-01-17
WO2002003978A3 (en) 2003-10-16
NZ523227A (en) 2005-04-29
ZA200300044B (en) 2004-05-06
CN100396283C (zh) 2008-06-25
KR20030031952A (ko) 2003-04-23
EP1372660A2 (en) 2004-01-02
AU7327101A (en) 2002-01-21

Similar Documents

Publication Publication Date Title
BR0112212A (pt) Uma combinação de inibidores de fbpase e agentes antidiabéticos úteis para o tratamento de diabetes
BR0212924A (pt) Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
BR0114758A (pt) Inibidores do receptor ep4 para tratamento de artrite reumatóide
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
BR0307772A (pt) Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
BR9913831A (pt) Processo para tratamento de arteriosclerose empregando um inibidor de ap2 e combinação
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
DE69905938D1 (de) Kombination von duloxetin mit nichtsteroid-entzündungshemmern für die behandlung von schmerz
GB0005251D0 (en) Therapeutic compounds
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
EE04416B1 (et) a1L- agonistide kasutamine uriiniinkontinentsuse raviks
EA200201175A1 (ru) Применение ингибиторов il-18 для лечения и/или предотвращения атеросклероза
PT1071422E (pt) Associações de riluzole e levodopa para o tratamento da doença de parkinson
BRPI0408491A (pt) tratamento da doença de alzheimer
KR960006915A (ko) 췌장염의 치료 조성물
BR0210101A (pt) Combinações antineoplásticas
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
GR3029489T3 (en) Use of leflunomid for the inhibition of interleukin 8.
ZA9711468B (en) New use of comt inhibitors

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: METABASIS THERAPEUTICS, INC. (US) , DAIICHI SANKYO

Free format text: TRANSFERIDO POR FUSAO DE: SANKYO COMPANY, LIMITED

B25A Requested transfer of rights approved

Owner name: METABASIS THERAPEUTICS, INC. (US)

Free format text: TRANSFERIDO DE: DAIICHI SANKYO COMPANY, LIMITED

B25G Requested change of headquarter approved

Owner name: METABASIS THERAPEUTICS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080132931/RJ DE 20/10/2008.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.